The Conversation (0)
Pfizer (NYSE:PFE) and Allergan discuss a potential deal, that could be the largest of the year.
Pfizer (NYSE:PFE) and Allergan discuss a potential deal, that could be the largest of the year.
According to an article on Pharmaceutical Processing:
Analysts speculated that Pfizer would have to pay $390 to $400 per share for Allergan, making the deal worth at least $153 billion. If a merger occurred, the combined company would have a market capitalization in excess of $330 billion, including Allergan’s present value of about $113 billion.
A merger could enable Pfizer, the world’s second-biggest drugmaker by revenue, to surpass Switzerland’s Novartis AG and regain the industry’s top spot. It would also add Allergan’s brand-name medicines for eye conditions, infections, and heart disease to Pfizer’s extensive portfolio of vaccines and drugs for cancer, pain, erectile dysfunction, and other conditions.
In separate statements, both companies on Thursday said they were in “preliminary friendly discussions.” Allergan Plc said there is no certainty that the talks with Pfizer Inc. will lead to a deal.
Click here to read the full article on Pharmaceutical Processing.